Aquestive Therapeutics, Inc. (AQST) Form 10-Q Quarterly Reports
Aquestive Therapeutics, Inc. (AQST) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: AQST
CIK: 1398733
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
KPMG LLP
Auditor SinceSince 12/31/2017 12:00:00 AM
Lead Engagement PartnerLindsay Phillips
Audit LocationShort Hills, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-16 | 2026-10-15 | PRIMARY DOCUMENT | 0001214659-26-012986 | View SEC Doc Filr Page |
| 3 | 2026-10-16 | 2026-10-15 | PRIMARY DOCUMENT | 0001214659-26-012983 | View SEC Doc Filr Page |
| 8-K | 2026-10-15 | 2026-10-15 | 8-K | 0001398733-26-000058 | View SEC Doc Filr Page |
| 8-K | 2026-10-14 | 2026-10-13 | 8-K | 0001398733-26-000056 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-10-07 | — | SCHEDULE 13G Filing | 0000897423-26-000125 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-10-07 | — | SCHEDULE 13G/A Filing | 0000897423-26-000124 | View SEC Doc Filr Page |
| 8-K | 2026-09-29 | 2026-09-29 | 8-K | 0001398733-26-000052 | View SEC Doc Filr Page |
| 8-K | 2026-09-25 | 2026-09-23 | 8-K | 0001398733-26-000048 | View SEC Doc Filr Page |
| 8-K | 2026-09-17 | 2026-09-14 | 8-K | 0001398733-26-000044 | View SEC Doc Filr Page |
| 4 | 2026-09-16 | 2026-09-15 | PRIMARY DOCUMENT | 0001214659-26-011731 | View SEC Doc Filr Page |
| 144 | 2026-09-15 | — | 144 Filing | 0001950047-26-009530 | View SEC Doc Filr Page |
| 4 | 2026-09-11 | 2026-09-09 | PRIMARY DOCUMENT | 0001214659-26-011596 | View SEC Doc Filr Page |
| 4 | 2026-09-10 | 2026-09-09 | PRIMARY DOCUMENT | 0001214659-26-011541 | View SEC Doc Filr Page |
| 4 | 2026-09-09 | 2026-09-08 | PRIMARY DOCUMENT | 0001214659-26-011539 | View SEC Doc Filr Page |
| 144 | 2026-09-09 | — | 144 Filing | 0001950047-26-009243 | View SEC Doc Filr Page |
| 4 | 2026-09-08 | 2026-09-03 | PRIMARY DOCUMENT | 0001214659-26-011475 | View SEC Doc Filr Page |
| 4 | 2026-08-18 | 2026-08-17 | PRIMARY DOCUMENT | 0001214659-26-010516 | View SEC Doc Filr Page |
| 4 | 2026-08-17 | 2026-08-14 | PRIMARY DOCUMENT | 0001214659-26-010474 | View SEC Doc Filr Page |
| 144 | 2026-08-17 | — | 144 Filing | 0001950047-26-008250 | View SEC Doc Filr Page |
| 10-Q | 2026-08-11 | 2026-06-30 | 10-Q | 0001398733-26-000042 | View SEC Doc Filr Page |
| 8-K | 2026-08-11 | 2026-08-11 | 8-K | 0001398733-26-000041 | View SEC Doc Filr Page |
| 8-K | 2026-08-10 | 2026-08-10 | 8-K | 0001398733-26-000035 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-27 | — | SCHEDULE 13G/A Filing | 0002012383-26-002183 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-15 | PRIMARY DOCUMENT | 0001214659-26-008663 | View SEC Doc Filr Page |
| 144 | 2026-07-15 | — | 144 Filing | 0001950047-26-007131 | View SEC Doc Filr Page |